Skip to content
Science Translational Medicine评分33

FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non–small cell lung cancer

Original articleChinese edition

No English body on site. Use the original article link above.